Open AccessSwitching from subcutaneous to intravenous erythropoietin α in haemodialysis patients requires a major dose increase
Author(s) -
Jack Galliford,
Rao Malasana,
Ken Farrington
Publication year - 2005
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfh899
Subject(s) - medicine , erythropoietin , dosing , dialysis , urology , albumin , ferritin , renal function , endocrinology , gastroenterology
A change in the licensing arrangements for the use of erythropoietin alpha in haemodialysis patients has required a switch in the route of administration from subcutaneous (SC) to intravenous (IV). Previous work suggested that the IV route was less efficacious but studies since the enforced switch have not confirmed this.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom